RE:January presentationfossi_2002 wrote:
All shareholders who consider Ceapro's development important should read the new presentation carefully.
Compared to the December presentation, one can see the importance of Yeast-Beta-Glucan. (page 7,21,22).
New development takes time.
The reorientation of Ceapro from a production company with 2 basic ingredients into a company with pharmaceuticals needs one thing above all: time! A lot of time!
Those who do not want to spend this time have the possibility to sell their shares.
If you want to spend your time senselessly, read the bullboard news of ISA - certainly 1000 in the last 12 months. What information have they brought us as shareholders? Absolutely none!!! Criticism - criticism - and again criticism!!! This person has no interest in Ceapro, he is only interested in his self-absorbed comments, to formulate this in complete sentences seems impossible to him.
I am convinced, even if our share rises sometime over 1,00$, he looks out again the argument, it stood already at 2,50$. He may be sitting on big losses and working off his frustration - who knows?
If Ceapro continues to grow in 2021 and 2022 as it has done so far, we will reach a turnover of approx. 20 million, which alone can be used to derive a higher share price.
You can be as critical as you want about the future projects, Cholesterol Reducer - Energy-Drink or Yeast-Beta-Glucan - they are not included in the current share price.
Excellent said.